News

A convergence of religion and spring… What does it mean for our mental health?

From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

What is new in research on COVID-19?

Empowerment has a significant correlation with patients’ overall mental and physical well-being, and has been central to the shift in conceptual framework of mental illness recovery towards a focus on resilience, strength, and control over one’s life.

"The buttonholes, the sizing, the facing, the characters. Printed in black on neckband and tail. The shape, the label, the labor, the color, the shade. The shirt."

This may be a pivotal moment in the history of psychedelics...

In this CME article, review the principles and applications of both invasive and noninvasive neuromodulation techniques for the treatment of mood disorders.

The trial aims to investigate the positive, negative, and cognitive domains of schizophrenia.

How can we fix our loneliness problem?

It has been 4 years of COVID-19. Are we in a better spot now than we were then?

"...seeking and longing for the garden of cherry blossoms..."

Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.

Welcome to the new column, “Second Thoughts… About Psychiatry, Psychology, and Psychotherapy.”

What is spring mania, and what are some effective clinical strategies for addressing it?

Given that two-thirds of patients treated for a major depressive episode will fail to achieve remission of symptoms after 2 or more treatment trials of first-line antidepressants, the probability of remission will further decrease with subsequent medication trials. Treatment strategies for patients with TRD include augmentation, where a medication is added to a current antidepressant versus switching to a different antidepressant.

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

Have you used AI in your clinical practice, research, or administration?

A psychiatrist reflects on the importance of time... and living in the moment.

The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.

A new study found that when glucose is either very high or low in patients with type 1 diabetes, cognition is slower; however, slightly above average glucose led to peak cognitive performance.

Here's how a good online reputation can help clinicians provide a positive patient experience.

“A narrow way through”: can H. Steven Moffic, MD, predict the future of psychiatry?

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

What is new in research on child and adolescent psychiatry?

"We were three men alone in a ward room built for fifty, dust film on the floor..."

Approximately 4 years of COVID-19…

Here’s why ADHD is a diagnosis of exclusion.

“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

What positivity emerged from the Oscars?